Insulet Corporation (PODD) Fair Value 2026

PODD · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.6 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-08-27, Insulet Corporation (PODD) trades at $143.41, versus a $106.55 median fair value across its 9 active models — 25.7% below the current price. QOC: 9.6/10. Value Trap Risk: 24/100 (SAFE). 9/13 models active. Within that set, the Bayesian DCF component alone returns $115.38.

Key Facts

Ticker
PODD
Price
$143.41
Quality Score
9.6/10
Value Trap Risk
24/100
Models Active
9/13
Last Updated
Strength: First Chicago suggests +18.0% upside with 64% confidence
Risk: Majority of models suggest overvaluation

Is Insulet Corporation (PODD) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Insulet Corporation (PODD) appears overvalued as of : the median of 9 independent fair value estimates is $106.55, 25.7% below the current price of $143.41. Estimates range from $41.19 to $231.47. PODD scores 9.6/10 on fundamental quality and 24/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. PODD’s -25.7% gap is wider than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Insulet Corporation Stock in 2026? →

What Fair Value Does Each Model Give PODD?

9 Intrinsic Value Models vs. Current Price ($143.41)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $115.38 -19.5%
Ensemble · Medium Conviction
 $106.55 -25.7%
Scenario · High Conviction
 $169.18 +18.0%
Intrinsic · High Conviction
 $54.27 -62.2%
Unlock the Full Matrix

Access 5 additional models including ML-RIV, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is PODD's Fair Value Range?

Spread across 9 independent models · $41.19 to $231.47

CirclFi's 9 active models place Insulet Corporation (PODD) between $41.19 and $231.47 per share, a spread of 179% of the median. The median of that range — $106.55 — is the fair value CirclFi publishes for PODD, against a current price of $143.41.

Low · ML-RIVHigh · Regime Cross
$41.19median $106.55$231.47
Where the range comes from
Most bearish modelML Residual Income$41.19
Most bullish modelRegime Cross-Sectional$231.47
Model agreement3 bullish · 6 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for PODD. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on PODD, not a CirclFi price target. How each model works →

What Is Insulet Corporation (PODD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Insulet Corporation at its current price of $143.41. The median intrinsic value is estimated at $106.55 (-25.7% vs price), with 6 models flagging overvaluation risk. Notably, Regime Cross sees the most upside at +61.4% (fair value: $231.47), while ML-RIV is the most conservative at -71.3% ($41.19). The spread between these extremes — +132.7% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, Bayesian DCF lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About PODD?

9 of 13 models are currently active for PODD. Of these, 3 models suggest upside while 6 models suggest overvaluation. Taken together, their median fair value for PODD is $106.55 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $115.38 on its own, implying -19.5% downside from the current price. See which stocks rank higher →

How Does PODD Rank in Medical Devices?

Among 157 Medical Devices stocks, PODD ranks #2 by Quality of Company score. CirclFi's QOC score of 9.6/10 evaluates 32 fundamental signals. A score of 9.6 places PODD in the top tier.

See all Most Undervalued Medical Devices Stocks →

As a healthcare company, Insulet Corporation operates in a sector where clinical trial success rate is a critical driver of valuation. Investors evaluating PODD should weigh these sector-specific dynamics alongside our model-derived fair values.

Is PODD a Value Trap?

CirclFi's Value Trap algorithm assigns PODD a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Insulet Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Insulet Corporation's fundamental quality profile registers 9.6/10. This exceptional score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +132.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PODD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PODD's 9 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Insulet Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

9 related Medical Devices stocks with 13-model coverage

IRMDIRADIMED CORPORATIONQOC 9.8GMEDGlobus Medical, Inc.QOC 9.2ITOCiTonic Holdings Ltd.QOC 2.5DXCMDexCom, Inc.QOC 9.2BWAYBrainsWay Ltd.QOC 2.6UFPTUFP Technologies, Inc.QOC 9.2LUNGPulmonx CorporationQOC 7.2STIMNeuronetics, Inc.QOC 6.2CATXPerspective Therapeutics, Inc.QOC 5.2

Read investment analysis: IRMD · GMED · ITOC · DXCM · BWAY · UFPT · LUNG · STIM · CATX

Which Other Stocks Have a Similar Quality Score to PODD?

7 companies across all industries closest to PODD’s Quality of Company score of 9.6/10.

ZMZoom Communications, Inc.QOC 9.6CRDOCredo Technology Group Holding LtdQOC 9.6NSSCNapco Security Technologies, Inc.QOC 9.6OMABGrupo Aeroportuario del Centro Norte, S.A.B. de C.V.QOC 9.6QLYSQualys, Inc.QOC 9.7PCTYPaylocity Holding CorporationQOC 9.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ZM · CRDO · NSSC · OMAB · QLYS · PCTY · NVDA

Where Does PODD Sit in CirclFi's Medical Devices Rankings?

PODD is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Insulet Corporation’s Valuation?

What is Insulet Corporation's intrinsic value in 2026?

CirclFi puts Insulet Corporation (PODD)'s intrinsic value at $106.55 — the median of 9 independent model estimates as of 2026-08-27, ranging from $41.19 to $231.47. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $115.38 on its own. The Quality of Company score is 9.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PODD overvalued or undervalued right now?

At $143.41, 3 of 9 active models suggest PODD may be undervalued, while 6 indicate potential overvaluation. The median of all 9 fair value estimates is $106.55, 25.7% below the current price of $143.41 — a consensus view that PODD is overvalued. The assessment depends on which methodology best fits Insulet Corporation's business model in Medical Devices.

What does a Quality of Company score of 9.6 mean for PODD?

Insulet Corporation's QOC of 9.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on PODD?

CirclFi analyzes PODD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on PODD?

Of the 9 models currently active on PODD, Regime Cross-Sectional is the most bullish at $231.47 per share, and ML Residual Income is the most bearish at $41.19. CirclFi's published fair value for PODD is the median of that range, $106.55, not either extreme. The gap between the two ends equals 179% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is PODD a value trap in 2026?

Insulet Corporation's Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Insulet Corporation (PODD) has a median fair value of $106.55 — 25.7% below the current price of $143.41 — as of 2026-08-27.” Source: circlfi.com/stock/PODD/ · Methodology
Primary sources for this PODD valuation
  • Financial statements: Insulet Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001145197) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PODD as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on PODD.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

5 models hidden for PODD Unlock All 9 — $39/mo